Ocular Hypertension (OHT) — Market Outlook, Epidemiology, Competitive Landscape, and Market Forecast Report — 2023 To 2033
Ocular hypertension (OHT) is the term used to describe a situation where a patient has an intraocular pressure (IOP) exceeding 21 mmHg. Typically asymptomatic, OHT is often incidentally discovered during routine ophthalmic examinations before it progresses into glaucomatous disorders. The underlying cause of OHT is impaired drainage of aqueous fluid from the front of the eye through the trabecular meshwork, requiring higher intraocular pressure for adequate drainage and resulting in chronically elevated IOP. It stands as a prominent modifiable risk factor for the development of glaucoma, with advancing age naturally increasing IOP and thereby raising the risk of ocular hypertension, particularly in elderly individuals. Additionally, a positive family history of glaucoma has been identified as another risk factor for OHT. In patients with OHT, the eye appears normal during the examination, featuring an open anterior chamber angle on gonioscopic evaluation. Fundus examination and imaging do not reveal signs of ocular nerve damage, and visual field findings remain normal. Uncontrolled OHT poses a significant risk of converting to glaucoma, with central corneal thickness (CCT) as a key risk factor for this transformation. Individuals with thin/low CCT measurements (less than 555 micrometers) are at a higher risk of OHT progressing to glaucoma than those with higher CCT values (greater than 488 micrometers). A more excellent cup-to-disc ratio observed during fundus examination is another statistically significant risk factor for the development of glaucoma. Additional risk factors for glaucoma conversion include:
- Age
- Race (with individuals of African ethnic background being predisposed)
- Gender (males having a higher risk)
- Pre-existing heart disease
Conversely, factors such as myopia, diabetes, and a family history of glaucoma are statistically insignificant. Management of OHT involves either treating the condition or opting for regular observation. The preferred treatment typically includes using beta-agonist or prostaglandin eyedrops administered once daily. Laser treatment and stent placement are alternative options shown to lower IOP. Treating OHT has been demonstrated to reduce the risk of glaucoma conversion from 9.5% to 4.4% over five years.
Thelansis’s “Ocular Hypertension (OHT) Market Outlook, Epidemiology, Competitive Landscape, and Market Forecast Report — 2023 To 2033” covers disease overview, epidemiology, drug utilization, prescription share analysis, competitive landscape, clinical practice, regulatory landscape, patient share, market uptake, market forecast, and key market insights under the potential Ocular Hypertension (OHT) treatment modalities options for eight major markets (USA, Germany, France, Italy, Spain, UK, Japan, and China).
KOLs insights of Ocular Hypertension (OHT) across 8 MM market from the centre of Excellence/ Public/ Private hospitals participated in the study. Insights around current treatment landscape, epidemiology, clinical characteristics, future treatment paradigm, and Unmet needs.
Ocular Hypertension (OHT) Market Forecast Patient Based Forecast Model (MS. Excel Based Automated Dashboard), which Data Inputs with sourcing, Market Event, and Product Event, Country specific Forecast Model, Market uptake and patient share uptake, Attribute Analysis, Analog Analysis, Disease burden, and pricing scenario, Summary, and Insights.
Thelansis Competitive Intelligence (CI) practice has been established based on a deep understanding of the pharma/biotech business environment to provide an optimized support system to all levels of the decision-making process. It enables business leaders in forward-thinking and proactive decision-making. Thelansis supports scientific and commercial teams in seamless CI support by creating an AI/ ML-based technology-driven platform that manages the data flow from primary and secondary sources.
